| |
Project IMPACT (US) [26]
|
APACHE III (US) [14]
|
Brazil APACHE III Study [27]
|
ENASSG (US/Europe) [22]
|
EURICUS-I (Europe) [28]
|
|---|
|
Admissions
|
40,435
|
17,440
|
1734
|
14,745
|
10,027
|
|
Units
|
55
|
42
|
10
|
137
|
89
|
|
Mean age
|
59.9
|
59
|
52
|
57.2
|
59.3
|
|
Male (%)
|
54.3
|
44.8
|
62
|
59.6
|
-
|
|
Surgical status (%)
| | | | | |
|
Nonsurgical
|
64.1
|
57.7
|
64.2
|
48.4
|
55.9
|
|
Elective
|
22.5
|
33.3
|
22.7
|
31.2
|
24.3
|
|
Emergency
|
13.4
|
9.0
|
13.1
|
19.6
|
19.8
|
|
Risk model
|
SAPS II
|
APACHE III
|
APACHE III
|
All
|
SAPS II
|
|
Mean probability
|
-
|
0.165*
|
0.204
|
-
|
0.223
|
|
Mortality (%)
| | | | | |
|
Unit
|
-
|
-
|
29
|
-
|
13.9
|
|
Hospital
|
18.2
|
16.5
|
34
|
21.8
|
20.0
|
| |
NICE (Netherlands) [29]
|
ASDI (Austria) [30]
|
PAEEC (Spain) [31]
|
PSSSG (Portugal) [32]
|
JSICM (Japan) [33]
|
|
Admissions
|
55,016
|
25,998
|
12,174
|
984
|
5,107
|
|
Units
|
18
|
31
|
86
|
19
|
33
|
|
Mean age
|
-
|
62.1
|
57.7
|
55.4
|
58.3
|
|
Male (%)
|
65.1
|
58.3
|
68
|
67.7
|
64.5
|
|
Surgical status (%)
| | | | | |
|
Nonsurgical
|
23.2
|
41.5
|
75.9
|
68.2
|
40.8
|
|
Elective
|
65.4
|
34.1
|
13.7
|
19.6
|
49.4
|
|
Emergency
|
11.4
|
24.4
|
10.4
|
12.2
|
9.8
|
|
Risk model
|
APACHE II
|
SAPS II
|
APACHE III
|
APACHE II
|
APACHE III
|
|
Mean probability
|
0.25†
|
0.193
|
0.198
|
0.335
|
0.181
|
|
Mortality (%)
| | | | | |
|
Unit
|
13.3†
|
-
|
-
|
24.5
|
-
|
|
Hospital
|
20.9†
|
17.6
|
21.2
|
32.0
|
18.2
|
- APACHE, Acute Physiology and Chronic Health Evaluation; ASDI, Austrian Center for Documentation and Quality Assurance in Intensive Care Medicine; ENASSG, European/North American Severity Study Group; EURICUS, European Study of Intensive Care Units; JSICM, Japanese Society of Intensive Care Medicine; NICE, National Intensive Care Evaluation; PAEEC, Project for the Epidemiological Analysis of Critical Care Patients; PSSSG, Portuguese Severity Scores Study Group; SAPS, Simplified Acute Physiology Score; -, not available from published report(s). * Observed and expected mortality are identical as this database represents the development population for the APACHE III model. † APACHE II mortality probability and mortality figures reported for 24,329 admissions eligible for APACHE II.
